TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00294918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
Study: NCT01996189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard needle BBraun Sterican® 23G and 25mm in length
Description: Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard needle BBraun Sterican® 23G and 25mm in length
Description: Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
Study: NCT04493502

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01869907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100 mg once daily by mouth during 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily by mouth during 14 days
Study: NCT04493502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3041658
Description: Administered IV
Study: NCT01771107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study: NCT01869907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25mg once daily by mouth during 14 days
Study: NCT00770653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride and Metformin
Description: Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
Study: NCT02022059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine = group A
Description: Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B placebo
Description: Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
Study: NCT01901159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: Oral doses of RO4995819 (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: Oral doses of RO4995819 (capsule)
Study: NCT04272918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Support Model
Description: Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education Program
Description: Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
Study: NCT02722564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self estimation of breath alcohol content

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breath alcohol content as measured by Alco Sensor IV device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drink a beer
Description: drink a beer, repeat until breath alcohol content 0.1
Study: NCT02726503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria.
Study: NCT00641433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxidized regenerated cellulose collagen-silver
Description: Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical silver sulfadiazine cream
Description: Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
Study: NCT01262417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: - use of resorbable membrane Seprafilm
Description: use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver

Intervention type: PROCEDURE
Group type: OTHER
Intervention: without resorbable barrier (seprafilm)
Description: non use of resorbable membrane during the first surgery for the resection of hepatic metastases
Study: NCT01941485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaveLight® Refractive Suite
Description: Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Description: Surgical procedure for treating refractive error based on corneal reshaping
Study: NCT00566774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full drug coverage
Description: Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual coverage
Description: Patients randomized to usual coverage will have no change in their existing benefits
Study: NCT01327625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin + N-acetylcystein + inhaled corticosteroid
Description: * Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months
Study: NCT04227808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvima 4 mg Oral Capsule
Description: The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
Study: NCT00860873

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)
Description: Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Description: Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)
Description: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)
Description: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
Study: NCT02156843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridorin
Description: 300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
Study: NCT02603146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: As described. Dosing will be based upon Screening IBW.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HCQ Placebo
Description: As described. Dosing will be based upon Screening IBW.
Study: NCT01452906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 and Omeprazole with food
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No PA21; Omeprazole with food
Description: The maximum dosage of Omeprazole will be 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 with food, Omeprazole 2hrs later
Description: The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
Study: NCT02429323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
Study: NCT02670317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
Study: NCT03965130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: PINTA study with glucagon

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Study
Description: The same participants will not receive glucagon during the PINTA study
Study: NCT04084158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection (JS001)
Description: Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Albumin-Bound
Description: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, Albumin-Bound
Description: Paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Drug
Description: carboplatin
Study: NCT06046924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables (F+V)
Description: Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaHCO3 Tablets
Description: Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
Study: NCT01964651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 50 mg
Description: JNJ-42165279 50 mg orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 100 mg
Description: JNJ-42165279 100 mg orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 100 mg
Description: JNJ-42165279 100 mg orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 30 mg
Description: JNJ-42165279 30 mg orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo orally administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo orally administered once daily for 10 days.
Study: NCT01869608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test 2 days post-partum
Description: Screening for type 2 diabetes after gestational diabetes mellitus.
Study: NCT03646877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air
Description: Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
Study: NCT04292275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biobeat Wrist Watch
Description: Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures. In addition, participants will be provided with a Biobeat wrist watch for continuous measurement and reporting of blood pressure data and with a smartphone to report weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.
Study: NCT02985827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rohto (r) Hydra
Description: Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rohto (r) Hydra
Description: Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane (r) Ultra
Description: Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systane (r) Ultra
Description: Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
Study: NCT03892200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Mouth Care
Description: Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.
Study: NCT03441477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nidek Tonoref III
Description: The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haag-Streit Goldmann Manual Tonometer
Description: Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIDEK CEM-530
Description: Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
Study: NCT01474317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G3 Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
Study: NCT03629964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wiersma Head Stabilizer
Description: Experimental device attached to treatment table.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlignRT system
Description: The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
Study: NCT00610870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 80mg/day before primary coronary intervention
Study: NCT01314196

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biceps resistance training and therapeutic exercises
Description: The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
Study: NCT04448964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.
Study: NCT03598036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1.